Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV-1 DNA vaccines.

A Fomsgaard1

  • 1Department of Virology, Statens Serum Institut, Copenhagen, Denmark. afo@ssi.dk

Immunology Letters
|March 5, 1999
PubMed
Summary
This summary is machine-generated.

DNA vaccines show promise for HIV-1 prevention and therapy. Secreted gp120 genes yielded high neutralizing antibody titers, while gene gun delivery with minimal epitopes induced specific CTL responses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First detection of tick-borne "Candidatus Neoehrlichia mikurensis" in Denmark 2011.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2012
Same author

Cases of travel-acquired dengue fever in Denmark 2001-2009.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2011
Same author

First identification of tick-borne encephalitis in Denmark outside of Bornholm, August 2009.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2009
Same author

Genome characterisation of the newly discovered avian influenza A H5N7 virus subtype combination.

Archives of virology·2006
Same author

An emerging avian influenza A virus H5N7 is a genetic reassortant of highly pathogenic genes.

Vaccine·2006
Same author

New avian influenza A virus subtype combination H5N7 identified in Danish mallard ducks.

Virus research·2005

Area of Science:

  • Immunology
  • Vaccinology
  • Molecular Biology

Background:

  • Human Immunodeficiency Virus type 1 (HIV-1) remains a significant global health challenge, with DNA vaccines emerging as a promising therapeutic and preventative strategy.
  • The development of effective HIV-1 vaccines is hindered by the lack of established correlates of protective immunity.
  • DNA vaccines offer advantages, including the induction of conformational antibodies, safety, and the ability to incorporate specific epitopes while excluding pathogenic elements.

Purpose of the Study:

  • To evaluate different DNA vaccine constructs for HIV-1, focusing on antibody and cytotoxic T lymphocyte (CTL) responses.
  • To compare the immunogenicity of native gp160, synthetic gp160, and gp120 genes, as well as fusion gene vaccines.
  • To assess the impact of delivery methods (muscle pre-treatment vs. gene gun) and epitope selection on vaccine efficacy.

Related Experiment Videos

Main Methods:

  • Comparison of DNA vaccines encoding native HIV-1 MN gp160, Rev-independent synthetic MNgp160, and MNgp120 genes using high-expression mammalian codons.
  • Evaluation of a fusion gene vaccine transferring the HIV-1 MN V3 loop to secreted HBsAg.
  • Assessment of gene gun immunization versus muscle pre-treatment for DNA vaccine delivery.
  • Induction and analysis of CTL responses to DNA vaccines containing minimal epitopes.

Main Results:

  • The gene encoding secreted gp120 elicited the highest antibody neutralizing titers.
  • A fusion gene vaccine incorporating the HIV-1 MN V3 loop also induced high and rapid antibody responses.
  • Gene gun immunization appeared to favor a Th2-biased response, while muscle pre-treatment showed no significant advantage.
  • All tested DNA vaccine candidates induced CTL responses, with gene gun delivery of minimal epitopes proving effective.

Conclusions:

  • Genes encoding secreted surface glycoproteins, such as gp120, may be preferable to membrane-bound envelopes for HIV-1 DNA vaccines.
  • Multivalent minigene vaccines incorporating numerous CTL epitopes are being developed to address HIV-1 and HLA diversity.
  • Gene gun delivery of DNA vaccines with selected minimal epitopes can effectively induce specific CTL responses, offering a viable strategy for vaccine development.